Tidal Investments LLC Raises Stake in Boston Scientific Corporation $BSX

Tidal Investments LLC lifted its position in Boston Scientific Corporation (NYSE:BSX) by 29.2% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 294,851 shares of the medical equipment provider’s stock after purchasing an additional 66,582 shares during the period. Tidal Investments LLC’s holdings in Boston Scientific were worth $12,584,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds also recently bought and sold shares of the company. National Pension Service lifted its position in shares of Boston Scientific by 7.1% in the second quarter. National Pension Service now owns 3,959,598 shares of the medical equipment provider’s stock valued at $168,996,000 after acquiring an additional 260,853 shares in the last quarter. Capital Analysts LLC grew its position in shares of Boston Scientific by 9.5% during the second quarter. Capital Analysts LLC now owns 53,256 shares of the medical equipment provider’s stock worth $2,273,000 after purchasing an additional 4,641 shares in the last quarter. C WorldWide Group Holding A S raised its stake in Boston Scientific by 55.6% during the 2nd quarter. C WorldWide Group Holding A S now owns 280,000 shares of the medical equipment provider’s stock valued at $11,950,000 after purchasing an additional 100,000 shares during the period. SVB Wealth LLC lifted its holdings in Boston Scientific by 62.3% in the 2nd quarter. SVB Wealth LLC now owns 5,714 shares of the medical equipment provider’s stock worth $244,000 after purchasing an additional 2,193 shares in the last quarter. Finally, NewEdge Advisors LLC lifted its holdings in Boston Scientific by 3.2% in the 2nd quarter. NewEdge Advisors LLC now owns 67,588 shares of the medical equipment provider’s stock worth $2,885,000 after purchasing an additional 2,127 shares in the last quarter. Institutional investors own 89.07% of the company’s stock.

Wall Street Analysts Forecast Growth

BSX has been the subject of a number of research analyst reports. Citigroup cut their price objective on shares of Boston Scientific from $70.00 to $61.00 and set a “buy” rating for the company in a report on Thursday, July 30th. Robert W. Baird set a $56.00 target price on shares of Boston Scientific in a research report on Thursday, July 30th. Zacks Research cut shares of Boston Scientific from a “hold” rating to a “strong sell” rating in a research note on Friday, June 5th. Wells Fargo & Company reduced their price target on shares of Boston Scientific from $55.00 to $50.00 and set an “equal weight” rating on the stock in a report on Thursday, July 30th. Finally, Mizuho reduced their price target on shares of Boston Scientific from $90.00 to $70.00 and set an “outperform” rating on the stock in a report on Wednesday, July 15th. Twenty-four research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat, Boston Scientific has a consensus rating of “Moderate Buy” and a consensus target price of $71.46.

Insider Activity at Boston Scientific

In other Boston Scientific news, CEO Michael F. Mahoney bought 186,240 shares of Boston Scientific stock in a transaction dated Monday, August 3rd. The shares were purchased at an average cost of $48.33 per share, for a total transaction of $9,000,979.20. Following the acquisition, the chief executive officer directly owned 1,590,024 shares in the company, valued at approximately $76,845,859.92. This represents a 13.27% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through this link. Also, Director Edward J. Ludwig purchased 5,000 shares of the stock in a transaction that occurred on Friday, July 31st. The stock was acquired at an average cost of $45.48 per share, with a total value of $227,400.00. Following the acquisition, the director owned 30,359 shares in the company, valued at $1,380,727.32. The trade was a 19.72% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders have acquired a total of 194,522 shares of company stock valued at $9,385,210 over the last 90 days. 0.34% of the stock is owned by corporate insiders.

Boston Scientific Stock Performance

NYSE:BSX opened at $43.00 on Friday. The company has a market cap of $62.31 billion, a price-to-earnings ratio of 17.41, a PEG ratio of 1.00 and a beta of 0.57. Boston Scientific Corporation has a 1 year low of $42.20 and a 1 year high of $105.65. The stock’s 50 day simple moving average is $47.00 and its two-hundred day simple moving average is $54.66. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.24 and a quick ratio of 0.74.

Boston Scientific (NYSE:BSX) last posted its earnings results on Wednesday, July 29th. The medical equipment provider reported $0.86 EPS for the quarter, beating analysts’ consensus estimates of $0.83 by $0.03. Boston Scientific had a return on equity of 19.28% and a net margin of 17.50%.The firm had revenue of $5.44 billion during the quarter, compared to the consensus estimate of $5.38 billion. During the same period in the prior year, the company earned $0.75 EPS. The company’s quarterly revenue was up 7.5% compared to the same quarter last year. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. As a group, equities analysts anticipate that Boston Scientific Corporation will post 3.29 earnings per share for the current fiscal year.

Boston Scientific announced that its Board of Directors has initiated a share repurchase program on Monday, May 18th that authorizes the company to repurchase $5.00 billion in shares. This repurchase authorization authorizes the medical equipment provider to repurchase up to 6.4% of its stock through open market purchases. Stock repurchase programs are usually an indication that the company’s leadership believes its shares are undervalued.

Boston Scientific Company Profile

Boston Scientific Corporation is a medical device company that develops, manufactures and markets products used in minimally invasive procedures. Its technologies are designed to diagnose and treat a range of medical conditions while supporting less invasive alternatives to traditional surgery.

The company’s products address cardiovascular, endoscopy, urology, pelvic health and neuromodulation applications. Its portfolio includes devices used in cardiac rhythm management and electrophysiology, structural heart procedures, peripheral and vascular interventions, gastrointestinal procedures, kidney stone and prostate treatments, and therapies for chronic pain and other neurological conditions.

Founded in 1979, Boston Scientific serves healthcare providers and patients in markets around the world.